Ces radiol. 2012, 66(3):289-295

Molecular imaging of the prostatic carcinoma - our experienceReview article

Jiří Ferda1, Jan Kastner1, Eva Ferdová1, Hynek Mírka1, Milan Hora2, Ondřej Hes3, Jindřich Fínek4, Boris Kreuzberg1
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Urologická klinika LF UK a FN, Plzeň
3 Šiklův ústav patologické anatomie LF UK a FN, Plzeň
4 Onkologické a radioterapeutické oddělení FN, Plzeň

The indications of the imaging methods underwent the exceptional evolution in last years. The united applications of the magnetic resonance imaging including the spectroscopy, diffusion imaging and pharmacokinetic evaluation helped to introduce the complex diagnostic algorithm to patients with pathologically elevated PSA levels. In cases of needed precise local staging, the most effective modality remains general T2 weighted imaging using high resolution data acquisition. The introduction of the choline labeled with fluorine 18 enables the routine clinical use of PET/CT not only in detection of the tumor, but also in detection of lymph node and skeleton dissemination. In cases of restaging of the disease including biochemically relapsing tumor, the 18F-FCH-PET/CT reached the important improvement in comparison to magnetic resonance. The tumor-induced osteoblastic activity in skeletally disseminated prostatic cancer could be assessed using 18F-NaF-PET/CT.

Keywords: prostatic carcinoma, spectroscopy, 18F-fluorocholine, 18F-natriumfluoride
Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR: Koncepční rozvoj výzkumné organizace 00669806 - FN Plzeň.

Accepted: August 15, 2012; Published: September 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Kastner J, Ferdová E, Mírka H, Hora M, Hes O, et al.. Molecular imaging of the prostatic carcinoma - our experience. Ces radiol. 2012;66(3):289-295.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167: 2435-2439. Go to original source...
    2. Vilanova JC, Comet J, Barcelo-Vidal C, et al. Periphreal zone prostate cancer in patients with elevated PSA and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. Radiology 2009; 253: 135-143. Go to original source... Go to PubMed...
    3. Doo KW, Sung DJ, Park BJ, et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 2012; 22(8): 1812-1819. Go to original source... Go to PubMed...
    4. Ferda J, Hora M, Hes O, et al. Zobrazení prostaty na 3T MRI u nemocných se zvýšenou hladinou PSA. Ces Radiol 2012; 66(1): 9-17. Go to original source...
    5. Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011; 21(9): 1970-1978. Go to original source... Go to PubMed...
    6. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259(2): 453-461. PubMed PMID: 21502392. Go to original source... Go to PubMed...
    7. Klijn S, De Visschere PJ, De Meerleer GO, Villeirs GM. Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection. Eur J Radiol 2012; 81(3): 411-416. Go to original source... Go to PubMed...
    8. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection - histopatologic correlation. Radiology 2010; 255: 89-99. Go to original source... Go to PubMed...
    9. Vargas HA, Wassberg C, Akin O, Hricak H. MR imaging of treated prostate cancer. Radiology 2012; 262(1): 26-42. Go to original source... Go to PubMed...
    10. Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F] choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2012; 81(4): 700-708. Go to original source... Go to PubMed...
    11. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2011; 80(2): e50-56. Go to original source... Go to PubMed...
    12. Soyka JD, Muster MA, Schmid DT, et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012; 39(6): 936-943. Go to original source... Go to PubMed...
    13. Graute V, Jansen N, Ubleis C, et al. Relationship between PSA kinetics and [18F] fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39(2): 271-282. Go to original source... Go to PubMed...
    14. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47(2): 287-297.
    15. Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, Langer M. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005; 55(1): 41-55. Go to original source... Go to PubMed...
    16. Lord M, Ratib O, Vallée JP. 18F-Fluorocholine integrated PET/MRI for the initial staging of prostate cancer. Eur J Nucl Med Mol Imaging 2011; 38(12): 2288. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content